Search research articles
Contact Us
Filters
Showing results (101-110 of 183) with videos related to
Page
of 19
Sort By:
Leukemia
|
November 20, 2019
BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials
Nora Liebers, Tobias Roider, Jan-Paul Bohn, et al.
Genes, Chromosomes & Cancer
|
October 18, 2012
High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas
Itziar Salaverria, Idoia Martin-Guerrero, Birgit Burkhardt, et al.
Leukemia & Lymphoma
|
September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance
Natali Pflug, Paula Cramer, Sandra Robrecht, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 8, 2016
Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival
Jasmin Corso, Kuan-Ting Pan, Roland Walter, et al.
Haematologica
|
May 2, 2016
Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Nathan H Fowler, Chan Yoon Cheah, Randy D Gascoyne, et al.
Cancer Letters
|
December 19, 2015
Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells
Taronish D Dubash, Christopher M Hoffmann, Felix Oppel, et al.
Leukemia Research
|
May 12, 2021
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues
Marco M Bühler, Junyan Lu, Sebastian Scheinost, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial
Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2013
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia
Sascha Dietrich, Jennifer Hüllein, Michael Hundemer, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 183) with videos related to
Sort By:
Page
of 19
Leukemia
|
November 20, 2019
BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials
Nora Liebers, Tobias Roider, Jan-Paul Bohn, et al.
Genes, Chromosomes & Cancer
|
October 18, 2012
High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas
Itziar Salaverria, Idoia Martin-Guerrero, Birgit Burkhardt, et al.
Leukemia & Lymphoma
|
September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance
Natali Pflug, Paula Cramer, Sandra Robrecht, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 8, 2016
Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival
Jasmin Corso, Kuan-Ting Pan, Roland Walter, et al.
Haematologica
|
May 2, 2016
Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Nathan H Fowler, Chan Yoon Cheah, Randy D Gascoyne, et al.
Cancer Letters
|
December 19, 2015
Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells
Taronish D Dubash, Christopher M Hoffmann, Felix Oppel, et al.
Leukemia Research
|
May 12, 2021
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues
Marco M Bühler, Junyan Lu, Sebastian Scheinost, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial
Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2013
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia
Sascha Dietrich, Jennifer Hüllein, Michael Hundemer, et al.
Page
of 19